TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. raised its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 65.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,692 shares of the company's stock after purchasing an additional 4,643 shares during the quarter. Cambridge Investment Research Advisors Inc.'s holdings in TransMedics Group were worth $787,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TMDX. Emerald Advisers LLC lifted its holdings in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after buying an additional 220,804 shares during the period. Sugar Maple Asset Management LLC acquired a new stake in TransMedics Group in the first quarter valued at $740,000. Capital Fund Management S.A. boosted its position in shares of TransMedics Group by 940.3% during the 4th quarter. Capital Fund Management S.A. now owns 125,880 shares of the company's stock worth $7,849,000 after purchasing an additional 113,780 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of TransMedics Group by 9.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 297,433 shares of the company's stock worth $18,545,000 after purchasing an additional 25,739 shares in the last quarter. Finally, Dana Investment Advisors Inc. grew its stake in shares of TransMedics Group by 55.6% during the 4th quarter. Dana Investment Advisors Inc. now owns 22,407 shares of the company's stock worth $1,397,000 after purchasing an additional 8,009 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 732 shares of TransMedics Group stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $123.88, for a total transaction of $90,680.16. Following the completion of the sale, the director directly owned 12,134 shares in the company, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,418 shares of company stock worth $1,512,613. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $128.73 on Monday. The company has a debt-to-equity ratio of 1.92, a quick ratio of 8.32 and a current ratio of 9.10. The business's fifty day moving average price is $122.32 and its two-hundred day moving average price is $88.76. The stock has a market cap of $4.35 billion, a PE ratio of 94.65 and a beta of 2.06. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The business's revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.35 earnings per share. On average, analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Oppenheimer boosted their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 17th. Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus target price of $127.33.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.